Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Orthocell Ltd ( (AU:OCC) ) is now available.
Orthocell Ltd has appointed its first Canadian distributor for its innovative nerve repair device, Remplir, marking a significant step in its global expansion strategy. The company has secured exclusive distributorships in Alberta and British Columbia, with further appointments expected to ensure comprehensive market coverage in Canada. The official launch will occur at the American Society for Surgery of the Hand meeting in Vancouver, with sales anticipated to begin in the December quarter. This strategic move is expected to accelerate Remplir’s international growth and improve patient outcomes, supported by Orthocell’s US-based marketing and medical education teams.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Ltd is a company operating in the medical device industry, specializing in nerve repair and regeneration solutions. Their primary product, Remplir, is a groundbreaking device aimed at improving outcomes in nerve repair surgeries. The company is focused on expanding its market presence globally, with a particular emphasis on the North American market.
Average Trading Volume: 547,725
Technical Sentiment Signal: Buy
Current Market Cap: A$320.2M
For detailed information about OCC stock, go to TipRanks’ Stock Analysis page.